• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to ''A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells'' [Euro. J. Pharmaceut. Biopharmaceut. 114 (2017) 305-316].

作者信息

Moretton Marcela A, Bernabeu Ezequiel, Grotz Estefanía, Gonzalez Lorena, Zubillaga Marcela, Chiappetta Diego A

机构信息

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Tecnología Farmacéutica I, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Química Biológica, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.

出版信息

Eur J Pharm Biopharm. 2017 Oct;119:454. doi: 10.1016/j.ejpb.2017.07.008. Epub 2017 Jul 26.

DOI:10.1016/j.ejpb.2017.07.008
PMID:28738178
Abstract
摘要

相似文献

1
Corrigendum to ''A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells'' [Euro. J. Pharmaceut. Biopharmaceut. 114 (2017) 305-316].《“一种葡萄糖靶向混合胶束制剂在乳腺癌细胞中优于Genexol”的勘误》[《欧洲药学与生物药剂学杂志》114 (2017) 305 - 316]
Eur J Pharm Biopharm. 2017 Oct;119:454. doi: 10.1016/j.ejpb.2017.07.008. Epub 2017 Jul 26.
2
A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells.一种以葡萄糖为靶点的混合胶束制剂在乳腺癌细胞中的表现优于健择。
Eur J Pharm Biopharm. 2017 May;114:305-316. doi: 10.1016/j.ejpb.2017.02.005. Epub 2017 Feb 10.
3
Corrigendum to "In vitro combinatorial anticancer effects of 5-fluorouracil and curcumin loaded N,O-carboxymethyl chitosan nanoparticles toward colon cancer and in vivo pharmacokinetic studies" [Eur. J. Pharmaceut. Biopharmaceut. 88 (2014) 238-251].
Eur J Pharm Biopharm. 2019 Jun;139:44-46. doi: 10.1016/j.ejpb.2019.03.009. Epub 2019 Mar 14.
4
Corrigendum to "pH-responsive and targeted delivery of chrysin via folic acid-functionalized mesoporous silica nanocarrier for breast cancer therapy" [Int. J. Pharmaceut. 631 (2023) 122555].
Int J Pharm. 2023 Oct 15;645:123363. doi: 10.1016/j.ijpharm.2023.123363. Epub 2023 Sep 9.
5
An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer.一项开放标签、随机、平行、III期试验，评估聚胶束配方紫杉醇与传统基于聚氧乙烯蓖麻油的紫杉醇相比，用于复发或转移性HER2阴性乳腺癌的疗效和安全性。
Cancer Res Treat. 2017 Jul;49(3):569-577. doi: 10.4143/crt.2016.289. Epub 2016 Sep 12.
6
Corrigendum to "Paclitaxel-loaded polymeric nanoparticles combined with chronomodulated chemotherapy on lung cancer: In vitro and in vivo evaluation" [Int. J. Pharmaceut. 516 (2017) 313-322].《紫杉醇负载聚合物纳米粒联合时辰调制化疗治疗肺癌：体内外评价》的勘误[《国际药学杂志》516（2017）313 - 322]
Int J Pharm. 2020 Jan 5;573:118878. doi: 10.1016/j.ijpharm.2019.118878. Epub 2019 Nov 26.
7
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.Genexol-PM（一种不含聚氧乙烯蓖麻油的紫杉醇聚合物胶束制剂）用于转移性乳腺癌患者的多中心II期试验。
Breast Cancer Res Treat. 2008 Mar;108(2):241-50. doi: 10.1007/s10549-007-9591-y. Epub 2007 May 3.
8
Corrigendum to ``Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells'' [Phytomedicine 22(9) (2015) 820-828].
Phytomedicine. 2019 Aug;61:152994. doi: 10.1016/j.phymed.2019.152994. Epub 2019 Jul 1.
9
A Phase II Study of Genexol(R) (paclitaxel) in Metastatic Breast Cancer.一项转移性乳腺癌中 Genexol(R)（紫杉醇）的 II 期研究。
Cancer Res Treat. 2001 Dec;33(6):451-7. doi: 10.4143/crt.2001.33.6.451.
10
Corrigendum to "Controlled release of NELL-1 protein from chitosan/hydroxyapatite-modified TCP particles" [Int. J. Pharmaceut. 511(1) (2016) 79-89].
Int J Pharm. 2020 Jan 25;574:118938. doi: 10.1016/j.ijpharm.2019.118938. Epub 2019 Dec 18.